Breast cancer

9:00-09:45

Advanced HER2-positive/HER2-low breast cancer

Patient with brain metastasis and stable extracranial disease:  when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis:  T-DXd  vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd 
Role of repeated biopsies to guide ADCs in HER2-low BC

Moderator:  Shereef Elsamany

Panel: 

09:45 –10:30

Role of anthracyclines in early breast cancer

  • When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

    When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

Moderator:Dr. Meteeb Alfohaidi

Panel:

10:30-11:00

Satellite Symposium

11:00-11:45

Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?

Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy

Moderator:Dr. Nasser Ali Al-Dhaibani Dr. Roaa Attieh

Panel:

11:45-12:00

Opening ceremony

12:00-14:00

Lunch & prayer

14:00-14:30

Satellite Symposium

14:30-15:00

Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?

Moderator: Dr. Ahmed Alwbari Dr. Hatim Al Maghrabi

15:00-15:45

Genomic tools in breast cancer

  •  chemotherapy in high risk lobular/mucinous BC?
  • Neoadjuvant therapy in premenopausal patients with lobular BC?
    Adjuvant therapy with node negative and node positive lobular BC?
    Adjuvant therapy in luminal BC with RS 16-25?
    Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours??
  • Oncotype DX and selection of neoadjuvant  hormonal vs chemotherapy  therapy
  • Role of interval Ki67 assessment with neoadjuvant  hormonal therapy

Moderator: Ahmed Alshehri

Panel: 

16:30-16:45

Break

16:45-17:30

Transition from hormonal-based to chemotherapy in metastatic BC??

  • Patients with early progression on CDK4-6 inhibitors: What is next??
  • When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
  • Any role of hormonal monotherapy after CDK4-6 inhibitors??
  • Biomarkers to guide subsequent therapies
  • Can we use one ADC after previous ADC??

Moderator:  Dr. Ahmed Alfaraj

Panel:

17:30-17:40

Concluding remarks Day 1

8:30-9:00

Setting-up clinical trials in Middle east: Challenges and opportunities

Moderators:

Dr. Emad Tashkandi Dr. Hosam Alghanmi

Panel:

09:00-09:45

Pancreatic cancer

  • Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
  • Best neoadjuvant strategy
  • 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
  • biomarkers for metastatic patients

Moderator: Dr. Abdullah Alsharm

Panel:

09:45-10:30

Biliary tract cancer

  • Immunetherapy in advanced BTC: Yes/No
  • Which agent?
  • Patient selection/tumour location?
  • Role of maintenance therapy?
  • Role of liquid biopsy/biomarker assessment

Moderator: Dr. Mohammed Algarni

panel:

10:30-10:45

Break

10:45-11:30

Perioperative therapy in Gastric cancer

  • Role of laparoscopy assessment before perioperative therapy?
  • What to do in patients with poor response to neoadjuvant therapy?
  • Role of biomarkers e.g MSI in decision-making before perioperative therapy?
  • Patients with limited peritoneal metastasis: Role of HIPEC?
  • Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?

Moderator:  Dr. Fahad Ibnshamsah

11:30-12:15

Challenges and dynamics of oncology health care

  • Financial toxicities and economic burden
  • Delayed access to oncology care
  • Cancer survivors: challenges and special requirements
  • Integration of service with primary health care for cancer survivors

Moderator: Dr. Esam Murshid

Panel:

 

12:15-12:45

Immunetherapy in CRC: Transition from metastatic to early stage

12:45-13:15

Satellite Symposium

13:15-13:20

Closing remarks

13:20-14:30

Prayer &Lunch